Zusammenfassung
Nach wie vor ist die Präeklampsie eine der häufigsten schwerwiegenden Schwangerschaftskomplikationen. Die Risikoabschätzung wird bis heute in der klinischen Routine vor allem durch die Risikofaktoren in der Anamnese bestimmt, und bis 2004 standen laut einer Veröffentlichung der WHO keine verlässlichen Parameter zur Prädiktion bereit. Neuere Biomarker, vor allem die Angiogenesefaktoren sFLT-1, „placental growth factor“ und Endoglin sowie „placental protein 13“, eröffnen aber, besonders in Kombination mit der Widerstandsmessung der A. uterina, erfolgversprechende Möglichkeiten zur Prädiktion der Präeklampsie. Auch die Genomforschung sowie die sog. Metabolomics und Proteomics zeigen neue mögliche Wege zum Verständnis von Pathomechanismen und Prädiktion. Im Beitrag soll versucht werden, die aktuellen Ergebnisse der Forschung und künftig mögliche Methoden zur Früherkennung von gefährdeten Patientinnen vorzustellen.
Abstract
Pre-eclampsia remains one of the most common severe complications in pregnancy. Clinical assessment is still done primarily through risk factors ascertained by anamnesis. According to a World Health Organisation release, until 2004 there still existed no dependable parameters for estimation of the risk. More recently biomarkers, above all the angiogenesis factors sFLT-1, placental growth factor, endoglin, and placental protein 13, show promise for better prediction of pre-eclampsia, especially combined with uterine artery resistance measurements. Genome research and so-called metabolomics and proteomics introduce new ways of understanding the prediction and pathomechanics of this disorder. Recent study results and new developments for early recognition of endangered patients are presented.
Literatur
Sargent IL, Smarson AK (n d) Immunology of pre-eclampsia; current views and hypothesis. BIOS Scientific Publishers ltd., Oxford
Lee ES, Oh MJ, Jung JW et al (n d) The levels of circulating vascular endothelial growth factor and soluble FLT-1 in pregnancies complicated by preeclampsia. J Korean Med Sci 22:94–98
Hofmeyer GJ, Atallah AN, Duley L (n d) Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane datbase Syst Rev CD 001059
Poston L, Briley AL, Seed PT (2006) Vitamin C and vitamin E in pregnant women at risk for preeclampsia (VIP trial): randomised placebo-controlled trial. Lancet 367:1145–1154
Duley L, Henderson-Amart DJ, Meher S, King JF (n d) Antiplatelet agents for preventing preeclampsia and ist complications (Review). Cochrane Database Syst Rev CD004659
Duckitt K, Harrington D (2005) Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies BMJ 330:565–567
Kaaja R (2008) Predictors and risk factors of pre-eclampsia. Minerva Ginecol 60(5):421–429
Jaccobsen B, Ladfors L, Milsom I (2004) Advanced maternal age an adverse perinatal outcome. Obstet Gynecol 104(4):727–733
Seoud MA, Nassar AH, Usta IM et al (2002) Impact of advanced maternal age on pregnancy outcome. Am J Perinatol 19(1):1–8
Ziadeh S, Yahaya A (2001) Pergnancy outcome at age 40 and older. Arch Gynecol Obstet 265:30–33
Pabinger I (2009) Thrombophilia and its impact on pregnancy. Thromb Res 123 (Suppl 3):S16–S21
Conde-AgudeloA, Villar J, Lindenheimer M (2004) World Health Organisation systematic Review of screening tests for preeclampsia. Obstet Gynecol 104:1367–1391
Meads CA, Cnossen JS, Meher S, Khan KS et al (2008) Methods of prevdiction and prevention of pre-eclampsia:systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess (Rockv) Vol 12:No 6
Carty DM, Delles CH, Dominiczak AF (2008) Novel biomarkers for predicting preeclampsia. Trends Cardiovasc Med 18:186–194
Ong CY, Lash G, Parker PN (n d) Angiogenesis and placental growth in normal and compromised pregnancies. Best Pract Res Clin Obstet Gynecol 14:969–980
Cooper JC, Sharkey AM, Charnock-Jones DS et al (1996) VEGF mRNA levels in placentae from pregnancies complicated by preeclampsia. Br J Obstet Gynecol 103:1191–1196
Kim SY, Ryu HM, Yang JH et al (n d) Increased sFLT-1 to PlGF ratio in women who subsequently develop preeclampsia. J Kor Med Sci 22:873–877
Koga K, Osuga Y, Yoshino O et al (2003) Elevated Serum soluble Vascular Endothelial Growth Factor Receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 88:2348–2351
Levine RJ, Maynard SE, Qian C et al (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350:672–683
Stepan H, Geide A, Faber R (2004) Soluble fms-like tyrosine kinase 1. N Engl J Med 351:2241–2242
Maynard SE, Min JY, Merchan J et al (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFLT-1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111:649–658
Venkatesha S, Toporsian M, Lam C et al (2006) Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12:642–649
Levine RJ, Lam C, Quian C et al (2006) Soluble endoglin and other circulating antiangiogenetic factors in preeclampsia. N Engl J Med 355:992–1005
Rana S, Karumanchi SA, Levine RJ et al (2007) Sequential changes in antiangiogenetic factors in early pregnancy and risk of developing preeclampsia. Hypertension 50:137–142
Stepan H, Unversucht A, Wessel N et al (2007) Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 49:818–824
Stepan H, Geipel A, Schwarz F et al (2008) Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am J Obstet Gynecol 198:175e171–175e176
Nicolaides KH, Bindra R, Turan OM et al (2006) A novel approach to first-trimester screening for early pre-eclampsia combinig serum PP13 and Doppler ultrasound. Ultrasound Obstet Gynecol 27:13–17
Burger O, Pick E, Zwickel J et al (n d) Placental Protein 13: Effects on cultured trophoblasts, and ist detection in human body fluids in normal and pathological pregancies
Chafetz I, Kuhnreich I, Sammar M et al (2007) First trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol 197:35e1–35e7
Kenyon GL, DeMarini DM, Fuchs E et al (2002) Defining the mandate of proteomics in the post-genomic era: Workshop report. Mol Cell Proteomics 1:763–780
Zimmerli LU, Schiffer E, Zürbig P et al (2008) Urinary proteomic biomarkers in coronary artery disease. Moll Cell Proteomics 7:290–298
Zhou H, Pisitkun T, Aponte A et al (2006) Exosomal fetuin a identified by proteomics: A novel urinary biomarker for detecting actute kidney injury. Kidney Int 70:1847–1857
Daviss B (2005) Growing pains for metabolomics. Scientist 19:25–28
Brindle JT, Antti H, Holmes E et al (2002) rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using H-1-HMR-based metabolomics. Nature Med 8:1439–1444
Brindle JT, Nicholson JK, Schofield PM et al (2003) Application of chemometrics to H-1-NMR spectroscopic data to investigate a relationship between human serum metabolic profiles and hypertension. Analyst 128:32–36
Kenny LC, Dunn WB, Ellis DI et al (2005) Novel biomarkers for preeclampsia detected using metabolomics and machine learning. Metabolomics 1:227–234
Dank
Vielen Dank an Frau Prof. Dr. K. Chalubinski, Frauenklinik der MUW Wien, für das zur Verfügung gestellte Bild in Abb. 1.
Interessenkonflikt
Keine Angaben
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Franz, M., Husslein, P. & Zeisler, H. Neue Methoden zur Früherkennung der Präeklampsie. Gynäkologe 42, 872–876 (2009). https://doi.org/10.1007/s00129-009-2426-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00129-009-2426-7